September 2, 2020
The IMPT recently released its updated MPT Product Development Database. The IMPT Secretariat conducted the annual update process between February and June of 2020 and launched the updated database in July 2020. Resources used to update the database included: product developer updates, published peer-reviewed literature, relevant scientific conferences, and publicly available funding data. The following […]
December 19, 2019
The IMPT offices are always a buzz with activity during the months of November and December. Giving Tuesday, World AIDS Day, as well as general end-of-the year wrap ups—it is a reminder that for organizations like ours, this time of year is a time for increased activism, awareness, and reflection. This year, as the IMPT […]
August 20, 2019
In sub-Saharan Africa, adolescent girls and young women are at the highest risk of acquiring HIV. However, as this is a heterogeneous population, the characteristics of these women can vary greatly. A one-size-fits-all approach simply will not work. In order for MPTs to have the greatest impact, approaches must be tailored to the populations where […]
July 22, 2019
Imagine if women could take one pill every day and be protected from unintended pregnancy AND HIV? And what if this pill was available within several years? We believe the fastest route to a contraceptive MPT is to combine two products that are ALREADY ON THE MARKET into a single pill. A dual-purpose pill has […]
November 5, 2018
We at Yaso Therapeutics are developing a vaginal gel, called Yaso-GEL, that uses a single proprietary drug to prevent pregnancy as well as genital herpes, gonorrhea, and chlamydia. The gel is mucoadhesive, non-irritating, relatively low-cost, and stable. Yaso-GEL aims to be an MPT that can fill the need for non-hormonal contraceptives and protect women from […]
October 17, 2018
Monoclonal antibodies are engineered proteins derived from a single parent cell and have been used in a diverse range of therapeutic applications due to their versatility and specificity. At Mapp Biopharmaceutical, Inc., we believe monoclonal antibodies are promising candidates for multipurpose prevention technologies (MPTs) when formulated as topical (e.g., films and rings) or injectable products. […]